A co-production process of desalted intestinal mucosal protein powder and heparin

A technology for intestinal mucosa and protein powder is applied in the field of co-production of desalted intestinal mucosa protein powder and heparinoid, which can solve problems such as environmental protection and production and operation problems, and achieve the effect of reducing production costs.

Active Publication Date: 2022-06-07
潢川县鹏升畜产品有限公司
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The technical status of the above-mentioned industry has brought great troubles to the environmental protection and production and operation of upstream crude heparin sodium enterprises. Therefore, it is urgent to develop an efficient co-production process to increase the added value of products and promote high-quality development.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A co-production process of desalted intestinal mucosal protein powder and heparin
  • A co-production process of desalted intestinal mucosal protein powder and heparin
  • A co-production process of desalted intestinal mucosal protein powder and heparin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] A desalted intestinal mucosal protein powder co-production process with heparin, including the following characteristic steps:

[0019] The process steps for desalting intestinal mucosal protein powder are:

[0020] S1, collect 500L of salt-containing protein wastewater in the production process of crude heparin sodium as raw material liquid, transfer the raw material liquid to the turnover box, circulate and filter through the ceramic membrane with a pore size of 10KD, and add purified water to the turnover tank during the filtration process to keep the raw material liquid volume unchanged, and detect the change in salinity of the raw material liquid. When the salinity of the detected raw material liquid drops below 0.1%, no more purified water is added to the turnover tank, and the volume of the feedstock liquid is 100L, that is, the interception solution, which is the concentrated desalted intestinal mucosal protein solution;

[0021] S2, to step S1 obtained in the conce...

Embodiment 2

[0039] A desalted intestinal mucosal protein powder co-production process with heparin, including the following characteristic steps:

[0040] The process steps for desalting intestinal mucosal protein powder are:

[0041] S1, collect 500L of salt-containing protein wastewater in the production process of crude heparin sodium as raw material liquid, transfer the raw material liquid to the turnover box, circulate and filter through the ceramic membrane with a pore diameter of 30KD, add purified water to the turnover tank during the filtration process to keep the raw material liquid volume unchanged, and detect the change in the salinity of the raw material liquid. When the salinity of the detected raw material liquid drops below 0.1%, no more purified water is added to the turnover tank, and the volume of the feedstock liquid is 100L, that is, the interception solution, which is the concentrated desalted intestinal mucosal protein solution;

[0042] S2, to step S1 obtained in the c...

Embodiment 3

[0057] A desalted intestinal mucosal protein powder co-production process with heparin, including the following characteristic steps:

[0058] The process steps for desalting intestinal mucosal protein powder are:

[0059] S1, collect 500L of salt-containing protein wastewater in the production process of crude heparin sodium as raw material liquid, transfer the raw material liquid to the turnover box, circulate and filter through the ceramic membrane with a pore diameter of 30KD, add purified water to the turnover tank during the filtration process to keep the raw material liquid volume unchanged, and detect the change in the salinity of the raw material liquid. When the salinity of the detected raw material liquid drops below 0.1%, no more purified water is added to the turnover tank, and the volume of the feedstock liquid is 100L, that is, the interception solution, which is the concentrated desalted intestinal mucosal protein solution;

[0060] S2, to step S1 obtained in the c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
pore sizeaaaaaaaaaa
Login to view more

Abstract

The invention relates to the field of biotechnology, in particular to a co-production process of desalted intestinal mucosal protein powder and heparinoid. The salt-containing protein waste water produced in the production process of crude heparin sodium is used as raw material, and ceramic membrane filtration technology, bio-enzyme degradation technology and low-temperature acid precipitation technology are used respectively to realize the co-production of desalted intestinal mucosal protein and high-quality heparin. The method comprises the following steps: circulating and filtering the salt-containing protein waste water produced in the production process of crude heparin sodium, and obtaining desalted intestinal mucosal protein powder after organic solvent precipitation, drying and crushing; Finally, heparinoids are obtained through nuclease degradation, low-temperature acid precipitation, hydrogen peroxide oxidation, low-magnification precipitation, drying, and pulverization in sequence. The co-production process is beneficial to reduce the discharge of waste water containing salt and the like, increase the added value of products, and has important economic value.

Description

Technical field [0001] The present invention relates to the field of biotechnology, specifically to a desalted intestinal mucosal protein powder and heparin co-production process. Background [0002] Heparin is the most effective and clinically available anticoagulant drug in the world, mainly used in cardiovascular and cerebrovascular diseases and hemodialysis treatment. In addition to anticoagulant and antithrombotic effects, heparin also has a variety of biological activities such as anti-tumor metastasis, anti-inflammatory, immunomodulatory, hypolipidemic, anti-membranial smooth muscle cell (SMC) hyperplasia, and promotion of fibrinolysis. Heparin molecules are composed of a series of complexly structured glycosaminoglycan molecules that cannot be prepared on a large scale by synthetic or biological fermentation. The current pharmacopoeia of various countries stipulates that the raw materials required for the production of heparin sodium need to be derived from the mucosa of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C08H1/00C08B37/00
CPCC08H1/00C08B37/0063C08B37/0003
Inventor 余璞斐徐袁陈讲一袁俊威黄帅
Owner 潢川县鹏升畜产品有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap